tiprankstipranks
Tharimmune signs nonbinding LOI to merge with Intract Pharma
PremiumThe FlyTharimmune signs nonbinding LOI to merge with Intract Pharma
2M ago
Tharimmune Expands Immunology Pipeline with Intract License
Premium
Company Announcements
Tharimmune Expands Immunology Pipeline with Intract License
2M ago
Tharimmune acquires global license, partners with Intract Pharma
Premium
The Fly
Tharimmune acquires global license, partners with Intract Pharma
2M ago
Tharimmune appoints Jules Haimovitz as strategic advisor
PremiumThe FlyTharimmune appoints Jules Haimovitz as strategic advisor
5M ago
Tharimmune to sell 659,545 shares at $3.16 in private placement
Premium
The Fly
Tharimmune to sell 659,545 shares at $3.16 in private placement
5M ago
Tharimmune announces Type C meeting with FDA for Phase 2 TH104 program
Premium
The Fly
Tharimmune announces Type C meeting with FDA for Phase 2 TH104 program
5M ago
Tharimmune establishes Scientific Advisory Board
PremiumThe FlyTharimmune establishes Scientific Advisory Board
7M ago
Tharimmune’s Active Common Stock Shares Update
Premium
Company Announcements
Tharimmune’s Active Common Stock Shares Update
10M ago
Tharimmune doses first patient in Phase 1 trial of TH104
Premium
The Fly
Tharimmune doses first patient in Phase 1 trial of TH104
10M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100